Natalizumab inhibits the expression of human endogenous retroviruses of the W family in multiple sclerosis patients: A longitudinal cohort study

Multiple Sclerosis

Volumn 20, Issue 2, 2014, Pages 174-182

  Arru, Giannina ^a   Leoni, Stefania ^a   Pugliatti, Maura ^a   Mei, Alessandra ^a   Serra, Caterina ^a   Delogu, Lucia Gemma ^a   Manetti, Roberto ^a   Dolei, Antonina ^a   Sotgiu, Stefano ^a   Mameli, Giuseppe ^a  

^a UNIVERSITY OF SASSARI   (Italy)

Author keywords

MSRV syncytin 1 HERV W; Multiple sclerosis; natalizumab

Indexed keywords

NATALIZUMAB; VIRUS PROTEIN; UNCLASSIFIED DRUG; WENV PROTEIN;

ADULT; ARTICLE; B LYMPHOCYTE; CELL SUBPOPULATION; CLINICAL ARTICLE; DISEASE COURSE; DRUG ACTIVITY; ENDOGENOUS RETROVIRUS; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; MIDDLE AGED; MONOCYTE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT OUTCOME; CELL VIABILITY; COHORT ANALYSIS; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; HUMAN CELL; LONGITUDINAL STUDY; VIRUS EXPRESSION;

MSRV/SYNCYTIN-1/HERV-W; MULTIPLE SCLEROSIS; NATALIZUMAB;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; COHORT STUDIES; ENDOGENOUS RETROVIRUSES; FEMALE; FLOW CYTOMETRY; GENE PRODUCTS, ENV; HUMANS; LEUKOCYTES, MONONUCLEAR; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PREGNANCY PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 84893599795     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513494957     Document Type: Article

References (32)

1. Steinman L, Martin R, Bernard C, et al. Multiple sclerosis: Deeper understanding of its pathogenesis reveals new targets for therapy. Annu Rev Neurosci. 2002 ; 25: 491-505
2. Gilden DH. Infectious causes of multiple sclerosis. Lancet Neurol. 2005 ; 4: 195-202
3. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: The role of infection. Ann Neurol. 2007 ; 61: 288-299
4. Franciotta D, Salvetti M, Lolli F, et al. B cells and multiple sclerosis. Lancet Neurol. 2008 ; 7: 852-858
5. Dolei A, Perron H. The multiple sclerosis-associated retrovirus and its HERV-W endogenous family: A biological interface between virology, genetics, and immunology in human physiology and disease. J Neurovirol. 2009 ; 15: 4-13
6. Antony JM, Ellestad KK, Hammond R, et al. The human endogenous retrovirus envelope glycoprotein, syncitin-1, regulates neuroinflammation and its receptor expression in multiple sclerosis: A role for endoplasmic reticulum chaperones in astrocytes. J Immunol. 2007 ; 179: 1210-1224
7. Mameli G, Astone V, Arru G, et al. Brains and peripheral blood mononuclear cells of multiple sclerosis (MS) patients hyperexpress MS-associated retrovirus/HERV-W endogenous retrovirus, but not human herpesvirus 6. J Gen Virol. 2007 ; 88: 264-274
8. Serra C, Mameli G, Arru G, et al. In vitro modulation of the multiple sclerosis (MS)-associated retrovirus by cytokines: Implications for MS pathogenesis. J Neurovirol. 2003 ; 9: 637-643
9. Mameli G, Serra C, Astone V, et al. Inhibition of multiple-sclerosis- associated retrovirus as biomarker of IFN therapy. J Neurovirol. 2008 ; 14: 73-77
10. Sotgiu S, Serra C, Mameli G, et al. Multiple sclerosis (MS)-associated retrovirus and MS prognosis: An observational study. Neurology. 2002 ; 59: 1071-1073
11. Sotgiu S, Arru G, Mameli G, et al. MSRV in early multiple sclerosis: A six-year follow-up of a Sardinian cohort. Mult Scler. 2006 ; 12: 698-703
12. Sotgiu S, Mameli G, Serra C, et al. Multiple sclerosis-associated retrovirus and progressive disability of multiple sclerosis. Mult Scler. 2010 ; 16: 1248-1251
13. Dolei A, Serra C, Mameli G, et al. Multiple sclerosis-associated retrovirus (MSRV) in Sardinian MS patients. Neurology. 2002 ; 58: 471-473
14. Mameli G, Poddighe L, Mei A, et al. Expression and activation by Epstein Barr virus of human endogenous retroviruses-W in blood cells and astrocytes: Inference for multiple sclerosis. PLoS One. 2012 ; 7: e44991
15. Martinez-Forero I, Pelaez A, Villoslada P. Pharmacogenomics of multiple sclerosis: In search for a personalized therapy. Expert Opin Pharmacother. 2008 ; 9: 3053-3067
16. Furlan R. Definition of non-responders: Biological markers. Neurol Sci. 2008 ; 29: 214-215
17. Ottervald J, Franzén B, Nilsson K, et al. Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers. J Proteomics. 2010 ; 73: 1117-1132
18. Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: A retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009 ; 8: 254-260
19. Putzki N, Yaldizli O, Mäurer M, et al. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: Results from a multi-center study in German speaking countries. Eur J Neurol. 2010 ; 17: 31-37
20. Coisne C, Mao W, Engelhardt B. Cutting edge: Natalizumab blocks adhesion but not initial contact of human T cells to the blood-brain barrier in vivo in an animal model of multiple sclerosis. J Immunol. 2009 ; 182: 5909-5913
21. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology. 1996 ; 46: 907-911
22. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011 ; 69: 292-302
23. Kurtzke JF. Rating neurological impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology. 1983 ; 33: 1444-1452
24. Mameli G, Poddighe L, Astone V, et al. Novel reliable real-time PCR for differential detection of MSRVenv and syncytin-1 in RNA and DNA from patients with multiple sclerosis. J Virol Methods. 2009 ; 161: 98-106
25. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 2001 ; 25: 402-408
26. Serra C, Biolchini A, Mei A, et al. Type III and I interferons increase HIV uptake and replication in human cells that overexpress CD4, CCR5, and CXCR4. AIDS Res Hum Retroviruses. 2008 ; 24: 173-180
27. Garcia-Montojo M, Dominguez-Mozo M, Arias-Leal A, et al. The DNA copy number of human endogenous retrovirus-W (MSRV-type) is increased in multiple sclerosis patients and is influenced by gender and disease severity. PLoS One. 2013 ; 8: e53623
28. Perron H, Hamdani N, Faucard R, et al. Molecular characteristics of human endogenous retrovirus type-W in schizophrenia and bipolar disorder. Transl Psychiatry. 2012 ; 2: e201
29. de Andrés C, Teijeiro R, Alonso B, et al. Long-term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in patients with multiple sclerosis. PLoS One. 2012 ; 7: e34103
30. Krumbholz M, Derfuss T, Hohlfeld R, et al. B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat Rev Neurol. 2012 ; 8: 613-623
31. Skarica M, Eckstein C, Whartenby KA, et al. Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients. J Neuroimmunol. 2011 ; 235: 70-76
32. Villar LM, García-Sánchez MI, Costa-Frossard L, et al. Immunological markers of optimal response to natalizumab in multiple sclerosis. Arch Neurol. 2012 ; 69: 191-197